November 18, 2020 11:12 AM EST

News briefing: Pfizer and Vivet get the OK to start gene therapy trial for rare liver disorder; Florida biotech inks $50M China deal

Vivet Therapeutics and Pfizer are one step closer to bringing a gene therapy for a rare liver disorder into the clinic.

The companies

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

News brief­ing: Pfiz­er and Vivet get the OK to start gene ther­a­py tri­al for rare liv­er dis­or­der; Flori­da biotech inks $50M Chi­na deal